The Year in Atherothrombosis

Journal of the American College of Cardiology

Volumn 55, Issue 14, 2010, Pages 1487-1498

  Sanz, Javier ^a   Moreno, Pedro R ^a   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

atherosclerosis; imaging; risk factors; thrombosis; vasculature

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENAZEPRIL; BEZAFIBRATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANGRELOR; CLOPIDOGREL; CONTRAST MEDIUM; GADOLINIUM; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TECHNETIUM 99M; THIAZIDE DIURETIC AGENT; THROMBIN INHIBITOR; TICAGRELOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG MEGADOSE; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; GENETIC MARKER; GENETIC VARIABILITY; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 77949899647     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.027     Document Type: Review

References (110)

1. Sipido K.R., Tedgui A., Kristensen S.D., et al. Identifying needs and opportunities for advancing translational research in cardiovascular disease. Cardiovasc Res 83 (2009) 425-435
2. Ford E.S., Li C., Zhao G., Pearson W.S., and Capewell S. Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults. Circulation 120 (2009) 1181-1188
3. Towfighi A., Zheng L., and Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 169 (2009) 1762-1766
4. Chan J.C., Malik V., Jia W., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301 (2009) 2129-2140
5. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., and Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373 (2009) 929-940
6. Patterson C.C., Dahlquist G.G., Gyurus E., Green A., and Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373 (2009) 2027-2033
7. Magnussen C.G., Venn A., Thomson R., et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood: evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart Study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol 53 (2009) 860-869
8. Nagel G., Arnold F.J., Wilhelm M., Link B., Zoellner I., and Koenig W. Environmental tobacco smoke and cardiometabolic risk in young children: results from a survey in south-west Germany. Eur Heart J 30 (2009) 1885-1893
9. Geerts C.C., Bots M.L., Grobbee D.E., and Uiterwaal C.S. Parental smoking and vascular damage in young adult offspring: is early life exposure critical?. The Atherosclerosis Risk in Young Adults study. Arterioscler Thromb Vasc Biol 28 (2008) 2296-2302
10. Moreno P.R., Sanz J., and Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol 53 (2009) 2315-2323
11. Higuchi A., Ohashi K., Kihara S., Walsh K., and Ouchi N. Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression. Circ Res 104 (2009) 1058-1065
12. Sluimer J.C., Kolodgie F.D., Bijnens A.P., et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 53 (2009) 1517-1527
13. Kalet-Litman S., Moreno P.R., and Levy A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 209 (2010) 28-31
14. Boyle J.J., Harrington H.A., Piper E., et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 174 (2009) 1097-1108
15. Yunoki K., Naruko T., Komatsu R., et al. Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes. Eur Heart J 30 (2009) 1844-1852
16. Song J., Sumiyoshi S., Nakashima Y., et al. Overexpression of heme oxygenase-1 in coronary atherosclerosis of Japanese autopsies with diabetes mellitus: Hisayama study. Atherosclerosis 202 (2009) 573-581
17. Abela G.S., Aziz K., Vedre A., Pathak D.R., Talbott J.D., and Dejong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol 103 (2009) 959-968
18. Pencina M.J., D'Agostino Sr. R.B., Larson M.G., Massaro J.M., and Vasan R.S. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 119 (2009) 3078-3084
19. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009) 1640-1645
20. Sierra-Johnson J., Fisher R.M., Romero-Corral A., et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic U.S. population. Eur Heart J 30 (2009) 710-717
21. Benderly M., Boyko V., and Goldbourt U. Apolipoproteins and long-term prognosis in coronary heart disease patients. Am Heart J 157 (2009) 103-110
22. Whitlock G., Lewington S., Sherliker P., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373 (2009) 1083-1096
23. Pischon T., Boeing H., Hoffmann K., et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 359 (2008) 2105-2120
24. Bell M.L., Peng R.D., Dominici F., and Samet J.M. Emergency hospital admissions for cardiovascular diseases and ambient levels of carbon monoxide: results for 126 United States urban counties, 1999-2005. Circulation 120 (2009) 949-955
25. Yeboah J., Folsom A.R., Burke G.L., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120 (2009) 502-509
26. Criqui M.H., Ninomiya J.K., Wingard D.L., Ji M., and Fronek A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 52 (2008) 1736-1742
27. Melander O., Newton-Cheh C., Almgren P., et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302 (2009) 49-57
28. McGillicuddy F.C., de la Llera Moya M., Hinkle C.C., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 119 (2009) 1135-1145
29. Eisenhardt S.U., Habersberger J., Murphy A., et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 105 (2009) 128-137
30. Elliott P., Chambers J.C., Zhang W., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302 (2009) 37-48
31. Rohatgi A., Owens A.W., Khera A., et al. Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. Arterioscler Thromb Vasc Biol 29 (2009) 1684-1690
32. Tani S., Nagao K., Anazawa T., et al. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 104 (2009) 464-469
33. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009) 412-423
34. Tsimikas S., Clopton P., Brilakis E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 119 (2009) 1711-1719
35. Kim D.H., Sabour S., Sagar U.N., Adams S., and Whellan D.J. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 102 (2008) 1540-1544
36. Oh J., Weng S., Felton S.K., et al. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 120 (2009) 687-698
37. Hagstrom E., Hellman P., Larsson T.E., et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119 (2009) 2765-2771
38. Tonelli M., Curhan G., Pfeffer M., et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120 (2009) 1784-1792
39. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
40. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009) 2553-2560
41. Samani N.J., Deloukas P., Erdmann J., et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol 29 (2009) 774-780
42. Jarinova O., Stewart A.F., Roberts R., et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol 29 (2009) 1671-1677
43. Paynter N.P., Chasman D.I., Buring J.E., Shiffman D., Cook N.R., and Ridker P.M. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 150 (2009) 65-72
44. Ikram M.A., Seshadri S., Bis J.C., et al. Genomewide association studies of stroke. N Engl J Med 360 (2009) 1718-1728
45. Chhatriwalla A.K., Nicholls S.J., Wang T.H., et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 53 (2009) 1110-1115
46. Philipp S., Bose D., Wijns W., et al. Do systemic risk factors impact invasive findings from virtual histology?. Insights from the international virtual histology registry. Eur Heart J 31 (2010) 196-202
47. Kim S.H., Hong M.K., Park D.W., et al. Impact of plaque characteristics analyzed by intravascular ultrasound on long-term clinical outcomes. Am J Cardiol 103 (2009) 1221-1226
48. Gurfinkel E., Vigliano C., Janavel J.V., et al. Presence of vulnerable coronary plaques in middle-aged individuals who suffered a brain death. Eur Heart J 30 (2009) 2845-2853
49. Stone GW. Results from landmark PROSPECT trial demonstrate the ability of Volcano's VH(R) IVUS imaging to identify plaques most likely to cause heart attacks. Available at: http://www.reuters.com/article/pressRelease/idUS181026+24-Sep-2009+PRN20090924 Accessed November 8, 2009.
50. Tanaka A., Imanishi T., Kitabata H., et al. Morphology of exertion-triggered plaque rupture in patients with acute coronary syndrome: an optical coherence tomography study. Circulation 118 (2008) 2368-2373
51. Li Q.X., Fu Q.Q., Shi S., et al. Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography. Heart 96 (2010) 196-201
52. Waxman S., Dixon S.R., L'Allier P., et al. In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. J Am Coll Cardiol Img 2 (2009) 858-868
53. Zanchetti A., Hennig M., Hollweck R., et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 120 (2009) 1084-1090
54. Xiong L., Deng Y.B., Zhu Y., Liu Y.N., and Bi X.J. Correlation of carotid plaque neovascularization detected by using contrast-enhanced US with clinical symptoms. Radiology 251 (2009) 583-589
55. Berry J.D., Liu K., Folsom A.R., et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 119 (2009) 382-389
56. Budoff M.J., Nasir K., McClelland R.L., et al. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 53 (2009) 345-352
57. Blaha M., Budoff M.J., Shaw L.J., et al. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardiol Img 2 (2009) 692-700
58. van Werkhoven J.M., Schuijf J.D., Gaemperli O., et al. Incremental prognostic value of multi-slice computed tomography coronary angiography over coronary artery calcium scoring in patients with suspected coronary artery disease. Eur Heart J 30 (2009) 2622-2629
59. Motoyama S., Sarai M., Harigaya H., et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 54 (2009) 49-57
60. Ibanez B., Cimmino G., Benezet-Mazuecos J., et al. Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis 202 (2009) 185-191
61. Rudd J.H.F., Myers K.S., Bansilal S., et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2 (2009) 107-115
62. Singh N., Moody A.R., Gladstone D.J., et al. Moderate carotid artery stenosis: MR imaging-depicted intraplaque hemorrhage predicts risk of cerebrovascular ischemic events in asymptomatic men. Radiology 252 (2009) 502-508
63. Ota H., Yu W., Underhill H.R., et al. Hemorrhage and large lipid-rich necrotic cores are independently associated with thin or ruptured fibrous caps: an in vivo 3T MRI study. Arterioscler Thromb Vasc Biol 29 (2009) 1696-1701
64. Miao C., Chen S., Macedo R., et al. Positive remodeling of the coronary arteries detected by magnetic resonance imaging in an asymptomatic population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 53 (2009) 1708-1715
65. Ibrahim T., Makowski M.R., Jankauskas A., et al. Serial contrast-enhanced cardiac magnetic resonance imaging demonstrates regression of hyperenhancement within the coronary artery wall in patients after acute myocardial infarction. J Am Coll Cardiol Img 2 (2009) 580-588
66. Tang T.Y., Howarth S.P., Miller S.R., et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 53 (2009) 2039-2050
67. Fujimoto S., Hartung D., Ohshima S., et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 52 (2008) 1847-1857
68. Sirol M., Moreno P.R., Purushothaman K.R., et al. Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. Circ Cardiovasc Imaging 2 (2009) 391-396
69. Lipinski M.J., Frias J.C., Amirbekian V., et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. J Am Coll Cardiol Img 2 (2009) 637-647
70. Nahrendorf M., Keliher E., Panizzi P., et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. J Am Coll Cardiol Img 2 (2009) 1213-1222
71. Xie F., Lof J., Matsunaga T., Zutshi R., and Porter T.R. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 119 (2009) 1378-1385
72. Kyrtatos P.G., Lehtolainen P., Junemann-Ramirez M., et al. Magnetic tagging increases delivery of circulating progenitors in vascular injury. J Am Coll Cardiol Intv 2 (2009) 794-802
73. Matter C.M., Stuber M., and Nahrendorf M. Imaging of the unstable plaque: how far have we got?. Eur Heart J 30 (2009) 2566-2574
74. Fung T.T., Rexrode K.M., Mantzoros C.S., Manson J.E., Willett W.C., and Hu F.B. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 119 (2009) 1093-1100
75. Meyers D.G., Neuberger J.S., and He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol 54 (2009) 1249-1255
76. Alberts M.J., Bhatt D.L., Mas J.L., et al. Three-year follow-up and event rates in the international Reduction of Atherothrombosis for Continued Health Registry. Eur Heart J 30 (2009) 2318-2326
77. Capewell S., O'Flaherty M., Ford E.S., and Critchley J.A. Potential reductions in United States coronary heart disease mortality by treating more patients. Am J Cardiol 103 (2009) 1703-1709
78. Yusuf S., Pais P., Afzal R., et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373 (2009) 1341-1351
79. Teo K.K., Sedlis S.P., Boden W.E., et al. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 54 (2009) 1303-1308
80. Maron D.J., Spertus J.A., Mancini G.B., et al. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Am J Cardiol 104 (2009) 1055-1062
81. Frye R.L., August P., Brooks M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (2009) 2503-2515
82. Serruys P.W., Morice M.-C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
83. Rahilly-Tierney C.R., Lawler E.V., Scranton R.E., and Gaziano J.M. Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age. Circulation 120 (2009) 1491-1497
84. Robinson J.G., Wang S., Smith B.J., and Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53 (2009) 316-322
85. Grover S.A., Kaouache M., Joseph L., Barter P., and Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med 169 (2009) 1775-1780
86. Goldenberg I., Boyko V., Tennenbaum A., Tanne D., Behar S., and Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 169 (2009) 508-514
87. Lee J.M., Robson M.D., Yu L.M., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54 (2009) 1787-1794
88. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361 (2009) 2113-2122
89. Calkin A.C., Drew B.G., Ono A., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120 (2009) 2095-2104
90. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182
91. Michos E.D., and Blumenthal R.S. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol 53 (2009) 931-935
92. Muntner P., Mann D., Razzouk L., et al. Is measuring C-reactive protein useful for guiding treatment in women > or = 60 years and men > or = 50 years of age?. Am J Cardiol 104 (2009) 354-358
93. Glynn R.J., Danielson E., Fonseca F.A., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360 (2009) 1851-1861
94. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
95. Verdecchia P., Staessen J.A., Angeli F., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374 (2009) 525-533
96. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
97. Wright Jr. J.T., Probstfield J.L., Cushman W.C., et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169 (2009) 832-842
98. Preis S.R., Hwang S.J., Coady S., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119 (2009) 1728-1735
99. Leal J., Gray A.M., and Clarke P.M. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J 30 (2009) 834-839
100. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
101. Dale A.C., Midthjell K., Nilsen T.I., Wiseth R., and Vatten L.J. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT study in Norway. Eur Heart J 30 (2009) 1372-1377
102. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009) 1765-1772
103. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53 (2009) 298-304
104. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
105. Berger J.S., Krantz M.J., Kittelson J.M., and Hiatt W.R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301 (2009) 1909-1919
106. Di Tullio M.R., Russo C., Jin Z., Sacco R.L., Mohr J.P., and Homma S. Aortic arch plaques and risk of recurrent stroke and death. Circulation 119 (2009) 2376-2382
107. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009) 1045-1057
108. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009) 2318-2329
109. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009) 2330-2341
110. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009) 1139-1151